CNS Pharmaceuticals (CNSP) Expected to Announce Quarterly Earnings on Wednesday

CNS Pharmaceuticals (NASDAQ:CNSP) will likely be releasing its results before the market opens on Wednesday, February 25th. Analysts expect CNS Pharmaceuticals to post earnings of ($5.09) per share for the quarter.

CNS Pharmaceuticals Price Performance

Shares of CNS Pharmaceuticals stock traded up $0.05 during trading on Friday, hitting $3.24. 10,112 shares of the company’s stock traded hands, compared to its average volume of 52,570. The firm’s fifty day moving average price is $5.62 and its 200 day moving average price is $6.83. CNS Pharmaceuticals has a twelve month low of $3.09 and a twelve month high of $55.20. The company has a market cap of $2.01 million, a PE ratio of -0.10 and a beta of 2.70.

Institutional Trading of CNS Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Boothbay Fund Management LLC acquired a new stake in shares of CNS Pharmaceuticals in the fourth quarter valued at about $71,000. Ikarian Capital LLC acquired a new position in shares of CNS Pharmaceuticals during the 4th quarter worth approximately $241,000. Finally, Armistice Capital LLC bought a new stake in shares of CNS Pharmaceuticals during the 2nd quarter worth approximately $335,000. 14.02% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $20.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.